Tevogen Bio’s Founder and CEO, Ryan Saadi, Recognized as a Health Care Innovator
Warren, N.J., March 26, 2025 – Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”), a clinical-stage specialty immunotherapy biotech company, is thrilled to announce that its Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This prestigious recognition underscores Dr. Saadi’s significant contributions to advancing healthcare innovation and accessibility not only in New Jersey but also on a global scale.
About Tevogen Bio
Tevogen Bio is a pioneering biotech company specializing in AI-driven immunotherapy drug discovery. The Company’s mission is to harness the power of artificial intelligence to develop novel therapeutics for various diseases, with a focus on oncology and autoimmune disorders. Tevogen Bio’s cutting-edge approach combines computational modeling with experimental validation, enabling the rapid identification of potential therapeutic targets and the design of optimized drug candidates.
Dr. Saadi’s Leadership and Commitment to Healthcare
Under Dr. Saadi’s leadership, Tevogen Bio has made significant strides in the field of immunotherapy, demonstrating a strong commitment to improving healthcare outcomes. With a background in both medicine and public health, Dr. Saadi brings a unique perspective to the Company, ensuring that its research efforts are not only scientifically sound but also socially responsible and accessible to a broad patient population.
Impact on Individuals
For individuals battling diseases such as cancer and autoimmune disorders, the advancements being made by Tevogen Bio and its team, led by Dr. Saadi, hold immense promise. The Company’s AI-driven approach to drug discovery could lead to the development of more effective and targeted therapies, ultimately improving patient outcomes and quality of life.
- Faster identification of potential therapeutic targets
- Design of optimized drug candidates
- Improved patient outcomes and quality of life
Impact on the World
The recognition of Dr. Saadi as a healthcare innovator not only underscores the potential impact of Tevogen Bio’s work on individual lives but also on a global scale. As the world continues to grapple with various health challenges, the advancement of AI-driven drug discovery could revolutionize the healthcare industry, making treatments more accessible and effective for millions of people around the world.
By combining the power of artificial intelligence with the expertise of its team, Tevogen Bio is at the forefront of this revolution, pushing the boundaries of what is possible in the realm of immunotherapy and beyond.
Conclusion
The recognition of Ryan Saadi, MD, MPH, as a health care innovator by NJBIZ is a testament to his leadership and commitment to advancing healthcare through AI-driven immunotherapy drug discovery at Tevogen Bio. This achievement not only highlights the potential impact on individual lives but also on a global scale, as the Company’s work could revolutionize the healthcare industry and make treatments more accessible and effective for millions of people around the world.
As the field of immunotherapy continues to evolve, Tevogen Bio, under Dr. Saadi’s guidance, is poised to make significant contributions to the betterment of healthcare and the lives of countless individuals. The future is bright for this innovative biotech company, and we look forward to witnessing the groundbreaking discoveries that lie ahead.
